410 related articles for article (PubMed ID: 16315004)
21. [18F]fluoromethylcholine (FCH) positron emission tomography/computed tomography (PET/CT) for lymph node staging of prostate cancer: a prospective study of 210 patients.
Poulsen MH; Bouchelouche K; Høilund-Carlsen PF; Petersen H; Gerke O; Steffansen SI; Marcussen N; Svolgaard N; Vach W; Geertsen U; Walter S
BJU Int; 2012 Dec; 110(11):1666-71. PubMed ID: 22520686
[TBL] [Abstract][Full Text] [Related]
22. [18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients.
Cimitan M; Bortolus R; Morassut S; Canzonieri V; Garbeglio A; Baresic T; Borsatti E; Drigo A; Trovò MG
Eur J Nucl Med Mol Imaging; 2006 Dec; 33(12):1387-98. PubMed ID: 16865395
[TBL] [Abstract][Full Text] [Related]
23.
Ferda J; Ferdová E; Baxa J; Fínek J; Topolčan O
Anticancer Res; 2018 Jul; 38(7):4139-4143. PubMed ID: 29970541
[TBL] [Abstract][Full Text] [Related]
24. [(11)C]choline PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy.
Rinnab L; Simon J; Hautmann RE; Cronauer MV; Hohl K; Buck AK; Reske SN; Mottaghy FM
World J Urol; 2009 Oct; 27(5):619-25. PubMed ID: 19234708
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of extraprostatic disease in the staging of prostate cancer by F-18 choline PET/CT: can PSA and PSA density help in patient selection?
Calabria F; Chiaravalloti A; Tavolozza M; Ragano-Caracciolo C; Schillaci O
Nucl Med Commun; 2013 Aug; 34(8):733-40. PubMed ID: 23680652
[TBL] [Abstract][Full Text] [Related]
26. Detection of recurrent prostate cancer with 18F-fluorocholine PET/CT in relation to PSA level at the time of imaging.
Kwee SA; Coel MN; Lim J
Ann Nucl Med; 2012 Jul; 26(6):501-7. PubMed ID: 22549847
[TBL] [Abstract][Full Text] [Related]
27. Acquisition with (11)C-choline and (18)F-fluorocholine PET/CT for patients with biochemical recurrence of prostate cancer: a systematic review and meta-analysis.
von Eyben FE; Kairemo K
Ann Nucl Med; 2016 Jul; 30(6):385-92. PubMed ID: 27173771
[TBL] [Abstract][Full Text] [Related]
28. The role of choline positron emission tomography/computed tomography in the management of patients with prostate-specific antigen progression after radical treatment of prostate cancer.
Picchio M; Briganti A; Fanti S; Heidenreich A; Krause BJ; Messa C; Montorsi F; Reske SN; Thalmann GN
Eur Urol; 2011 Jan; 59(1):51-60. PubMed ID: 20869161
[TBL] [Abstract][Full Text] [Related]
29. Recurrent prostate cancer after radical prostatectomy: restaging performance of 18F-choline hybrid PET/MRI.
Achard V; Lamanna G; Denis A; De Perrot T; Mainta IC; Ratib O; Iselin C; Miralbell R; Garibotto V; Zilli T
Med Oncol; 2019 Jun; 36(8):67. PubMed ID: 31190232
[TBL] [Abstract][Full Text] [Related]
30. Comparison between conventional imaging (abdominal-pelvic computed tomography and bone scan) and [(18)F]choline positron emission tomography/computed tomography imaging for the initial staging of patients with intermediate- tohigh-risk prostate cancer: A retrospective analysis.
Evangelista L; Cimitan M; Zattoni F; Guttilla A; Zattoni F; Saladini G
Scand J Urol; 2015; 49(5):345-53. PubMed ID: 25649494
[TBL] [Abstract][Full Text] [Related]
31. Prostate-specific antigen velocity versus prostate-specific antigen doubling time for prediction of 11C choline PET/CT in prostate cancer patients with biochemical failure after radical prostatectomy.
Giovacchini G; Picchio M; Parra RG; Briganti A; Gianolli L; Montorsi F; Messa C
Clin Nucl Med; 2012 Apr; 37(4):325-31. PubMed ID: 22391699
[TBL] [Abstract][Full Text] [Related]
32. Usefulness of 18F-fluorocoline PET/CT in prostate cancer patients with biochemical recurrence: Influence of PSA kinetics and hormone therapy.
Triviño-Ibáñez EM; Puche-Sanz I; Gómez-Río M; Cózar Olmo JM; Llamas-Elvira JM; Rodríguez-Fernández A
Med Clin (Barc); 2019 Jul; 153(2):56-62. PubMed ID: 30660434
[TBL] [Abstract][Full Text] [Related]
33. Influence of PSA, PSA velocity and PSA doubling time on contrast-enhanced 18F-choline PET/CT detection rate in patients with rising PSA after radical prostatectomy.
Schillaci O; Calabria F; Tavolozza M; Caracciolo CR; Finazzi Agrò E; Miano R; Orlacchio A; Danieli R; Simonetti G
Eur J Nucl Med Mol Imaging; 2012 Apr; 39(4):589-96. PubMed ID: 22231016
[TBL] [Abstract][Full Text] [Related]
34. 18F-choline and/or 11C-acetate positron emission tomography: detection of residual or progressive subclinical disease at very low prostate-specific antigen values (<1 ng/mL) after radical prostatectomy.
Vees H; Buchegger F; Albrecht S; Khan H; Husarik D; Zaidi H; Soloviev D; Hany TF; Miralbell R
BJU Int; 2007 Jun; 99(6):1415-20. PubMed ID: 17428249
[TBL] [Abstract][Full Text] [Related]
35. 18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients.
Beheshti M; Imamovic L; Broinger G; Vali R; Waldenberger P; Stoiber F; Nader M; Gruy B; Janetschek G; Langsteger W
Radiology; 2010 Mar; 254(3):925-33. PubMed ID: 20177103
[TBL] [Abstract][Full Text] [Related]
36. Role of whole-body 18F-choline PET/CT in disease detection in patients with biochemical relapse after radical treatment for prostate cancer.
Pelosi E; Arena V; Skanjeti A; Pirro V; Douroukas A; Pupi A; Mancini M
Radiol Med; 2008 Sep; 113(6):895-904. PubMed ID: 18414809
[TBL] [Abstract][Full Text] [Related]
37. Long-term Results of a Comparative PET/CT and PET/MRI Study of 11C-Acetate and 18F-Fluorocholine for Restaging of Early Recurrent Prostate Cancer.
Lamanna G; Tabouret-Viaud C; Rager O; Jorcano S; Vees HJ; Seimbille Y; Zaidi H; Ratib O; Buchegger F; Miralbell R; Zilli T; Garibotto V
Clin Nucl Med; 2017 May; 42(5):e242-e246. PubMed ID: 28240662
[TBL] [Abstract][Full Text] [Related]
38. 18F-Fluorocholine PET/CT Complementing the Role of Dynamic Contrast-Enhanced MRI for Providing Comprehensive Diagnostic Workup in Prostate Cancer Patients With Suspected Relapse Following Radical Prostatectomy.
Vadi SK; Singh B; Basher RK; Watts A; Sood AK; Lal A; Kakkar N; Singh SK
Clin Nucl Med; 2017 Aug; 42(8):e355-e361. PubMed ID: 28525448
[TBL] [Abstract][Full Text] [Related]
39. Pattern of occult nodal relapse diagnosed with (18)F-fluoro-choline PET/CT in prostate cancer patients with biochemical failure after prostate-only radiotherapy.
Lépinoy A; Cochet A; Cueff A; Cormier L; Martin E; Maingon P; Bosset JF; Brunotte F; Créhange G
Radiother Oncol; 2014 Apr; 111(1):120-5. PubMed ID: 24780635
[TBL] [Abstract][Full Text] [Related]
40. (11)C-Choline PET/CT for restaging prostate cancer. Results from 4,426 scans in a single-centre patient series.
Graziani T; Ceci F; Castellucci P; Polverari G; Lima GM; Lodi F; Morganti AG; Ardizzoni A; Schiavina R; Fanti S
Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1971-9. PubMed ID: 27277279
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]